Alphamab Oncology (HKSE:09966) Long-Term Debt : HK$161.5 Mil (As of Jun. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Alphamab Oncology Long-Term Debt?

Alphamab Oncology's Long-Term Debt for the quarter that ended in Jun. 2024 was HK$161.5 Mil.

Alphamab Oncology's quarterly Long-Term Debt declined from Jun. 2023 (HK$218.8 Mil) to Dec. 2023 (HK$191.4 Mil) and declined from Dec. 2023 (HK$191.4 Mil) to Jun. 2024 (HK$161.5 Mil).

Alphamab Oncology's annual Long-Term Debt declined from Dec. 2021 (HK$188.4 Mil) to Dec. 2022 (HK$167.5 Mil) but then increased from Dec. 2022 (HK$167.5 Mil) to Dec. 2023 (HK$191.4 Mil).

Alphamab Oncology Long-Term Debt Historical Data

The historical data trend for Alphamab Oncology's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alphamab Oncology Long-Term Debt Chart

Alphamab Oncology Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Debt

Get a 7-Day Free Trial

223.94

25.31

188.36

167.51

191.41

Alphamab Oncology Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Long-Term Debt	Get a 7-Day Free Trial									203.65	167.51	218.76	191.41	161.48

Alphamab Oncology (HKSE:09966) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Alphamab Oncology Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Alphamab Oncology's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Alphamab Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alphamab Oncology (HKSE:09966) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

3NK:Germany

Address

No. 175 Fangzhou Road, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215127

Website

https://www.alphamabonc.com

Alphamab Oncology is a clinical-stage biopharmaceutical company in China with a fully integrated proprietary biologics platform in bispecifics and protein engineering. The company through its subsidiaries is engaged in the discovery, development manufacturing, and commercialization of biotherapeutics for cancer treatment. Its product pipeline includes various drug candidates such as KN035 (Envida), KN046, KN026, JSKN003, and KN019 among others in different stages of development.

Executives

South Dakota Trust Company Llc	2301 Trustee
Xu Ting	2305 Beneficiary of a trust
Liu Yang	2307 Founder of a discretionary trust who can infl
Rubymab Ltd.	2101 Beneficial owner
Pang Kee Chan Hebert
Highbury Investment Pte Ltd	2201 Interest of corporation controlled by you
Gic Special Investments Private Limited	2102 Investment manager
Gic Private Limited	2201 Interest of corporation controlled by you
Gic (ventures) Pte. Ltd.	2201 Interest of corporation controlled by you
Advantech Capital Ii Investment Partners Limited
Advantech Capital Ii Alphamab Partnership L.p.
Advantech Capital Partners Ii Limited
Advantech Capital Investment I Limited
Advantech Capital Ii Master Investment Limited
Advantech Capital Ii L.p.

Alphamab Oncology Headlines

No Headlines